<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443129</url>
  </required_header>
  <id_info>
    <org_study_id>185/14</org_study_id>
    <nct_id>NCT02443129</nct_id>
  </id_info>
  <brief_title>Swept Source Enhanced Depth Imaging Optical Coherence Tomography</brief_title>
  <official_title>Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would be interested in applying the enhanced depth imaging technique to&#xD;
      swept source optical coherence tomography, by modifying the acquisition protocol. Doing so,&#xD;
      the investigators hope to improve the visualization of the choroid and perhaps even of the&#xD;
      sclera.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A structurally and functionally normal choroidal vasculature is essential for retinal&#xD;
      function. The status of the choroid appears to be a crucial determinant in the pathogenesis&#xD;
      of diseases such as age-related choroidal atrophy, myopic chorioretinal atrophy, central&#xD;
      serous chorioretinopathy, chorioretinal inflammatory diseases, and tumors.&#xD;
&#xD;
      The in vivo structure of the choroid in health and disease is incompletely visualized with&#xD;
      traditional imaging modalities, including indocyanine green angiography and ultrasonography.&#xD;
&#xD;
      Optical coherence tomography (OCT) is an established medical imaging technique that uses&#xD;
      light to capture micrometer-resolution, three-dimensional images from within optical&#xD;
      scattering media. OCT is based on low-coherence interferometry. Nowadays, it is essential for&#xD;
      managing retinal conditions.&#xD;
&#xD;
      Unfortunately, standard spectral domain optic coherence tomography (SD-OCT) is of limited use&#xD;
      in imaging choroidal morphology.&#xD;
&#xD;
      A modification to the standard technique, termed enhanced depth imaging optical coherence&#xD;
      tomography (EDI-OCT), is able to image the choroid with better clarity using commercial&#xD;
      SD-OCTs.&#xD;
&#xD;
      With the advent of enhanced depth imaging optical coherence tomography (EDI-OCT), detailed&#xD;
      visualisation of the choroid in vivo has been made possible possible. Measurements of&#xD;
      choroidal thickness (CT) have also enabled new directions in research to study normal and&#xD;
      pathological processes within the choroid.&#xD;
&#xD;
      However, EDI-OCT has its own limitations: the outer choroidal border cannot always be&#xD;
      visualized and choroidal details sometime lack clarity.&#xD;
&#xD;
      A new generation of OCTs has been made available, based on swept-source technology.&#xD;
&#xD;
      Swept source OCT (SS-OCT) has been shown to be more precise than spectral domain EDI-OCT in&#xD;
      measuring choroidal thickness.&#xD;
&#xD;
      Our department is now using two OCTs, one is a SD- OCT (Canon HS-100), the other one a SS-&#xD;
      OCT (Topcon DRI Atlantis).&#xD;
&#xD;
      The investigators would be interested in applying the EDI technique to SS- OCT, by modifying&#xD;
      the acquisition protocol. Doing so, the investigators hope to improve the visualization of&#xD;
      the choroid and perhaps even of the sclera.&#xD;
&#xD;
      This modification is based on the technique described by Spaide for SD-OCT.&#xD;
&#xD;
      From the patient's perspective, it only involves spending more time fixing the green stimulus&#xD;
      (about 4 minutes instead of 2, in order to follow the swept-source EDI protocol in addition&#xD;
      to standard swept source).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in chorio-retinal depth and morphology between healthy and diseased subjects</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Retina, Choroid, Sclera</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18-99 year old male + female&#xD;
Intervention:&#xD;
DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mydramide only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the clinics undergoing pupil dilation&#xD;
Intervention:&#xD;
Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mydramide and ephrine 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the clinics undergoing pupil dilation&#xD;
Intervention:&#xD;
Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All patients presenting with RD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with retinal detachment&#xD;
Intervention:&#xD;
RD surgery DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impact of previous grid treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients after grid laser&#xD;
Intervention:&#xD;
DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of glaucoma medications</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment&#xD;
Intervention:&#xD;
If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of arteritic/non-arteritic AION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).&#xD;
Longitudinal arm with newly diagnosed patients for 2 years follow-up&#xD;
Intervention:&#xD;
DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVAMD poorly responsive to Rx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin&#xD;
Intervention:&#xD;
DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective analysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients pictured with DRI-OCT&#xD;
Intervention:&#xD;
DRI-1 Swept source OCT, Atlantis, Topcon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DRI-1 Swept source OCT, Atlantis, Topcon</intervention_name>
    <description>Fundus imaging</description>
    <arm_group_label>All patients presenting with RD</arm_group_label>
    <arm_group_label>Effect of arteritic/non-arteritic AION</arm_group_label>
    <arm_group_label>Effect of glaucoma medications</arm_group_label>
    <arm_group_label>Impact of previous grid treatment</arm_group_label>
    <arm_group_label>NVAMD poorly responsive to Rx</arm_group_label>
    <arm_group_label>Retrospective analysis</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>mydramide and ephrine 10%</arm_group_label>
    <arm_group_label>mydramide only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to sit for OCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Media opacities precluding fundus view&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

